Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Delayed Quote. Delayed  - 10/25 10:00:21 pm
40.19 USD   -0.54%
04:58a ST JUDE MEDICAL : . Jude, short-seller trade blame in cybersecurity ..
10/21 GLOBAL BLOOD TE : Abbott Laboratories, Ortho Clinical Diagnostics, B..
10/20 ABBOTT LABORATO : People's Republic of China Clears Abbott Acquisiti..
News SummaryMost relevantAll newsSector news 

Abbott Laboratories : Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery

share with twitter share with LinkedIn share with facebook
share via e-mail
04/20/2012 | 03:05pm CEST

ABBOTT PARK, Ill., April 20, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today U.S. Food and Drug Administration clearance to use its iFS Advanced Femtosecond Laser to create bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.

The iFS Laser is currently used to create LASIK flaps and other corneal incisions in the eye and is the fifth generation of IntraLase technology, which has been used in more than 5 million procedures worldwide.

Nearly 3 million patients undergo cataract surgery each year in the United States. With this new clearance, the iFS Laser now gives surgeons the ability to make precise, bladeless arcuate incisions during surgery and customize the incision for each individual patient.

Factors such as placement, length, depth and radius of curvature can influence the surgeon's desired change to the cornea. These parameters can be difficult to control through traditional incisions made by hand using surgical knives. Now, using the iFS Laser, arcuate incisions can be performed with greater precision, predictability and customization than is possible with a manual technique.

"This is a major advancement and expansion of our Femtosecond laser technology," said Jim Mazzo, senior vice president, Abbott Medical Optics. "Abbott has been a pioneer in the ophthalmic use of Femtosecond lasers, and this new use of our technology demonstrates our leadership position in this very dynamic and competitive market. This is an important step as we look to utilize Femtosecond laser technology as a potential standard of care during the cataract procedure."

Study data support that the iFS Femtosecond laser creates arcuate incisions safely and effectively as prescribed by the physician, and complies with applicable safety standards.

This new use of Abbott's iFS Femtosecond laser is available now in the United States.

About Abbott Medical Optics (AMO)

Abbott Medical Optics is focused on delivering life-improving vision technologies to people of all ages. The company offers a comprehensive portfolio of cataract, refractive and eye care products. Products in the cataract line include monofocal and multifocal intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. Products in the refractive line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices; excimer laser vision correction systems and treatment cards. Products in the eye care line include disinfecting solutions, enzymatic cleaners, lens rewetting drops and artificial tears.

For more information, please visit www.abbottmedicaloptics.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


share with twitter share with LinkedIn share with facebook
share via e-mail
04:58a ST JUDE MEDICAL : . Jude, short-seller trade blame in cybersecurity case
10/24 ABBOTT LABORATORIES : Other Events (form 8-K)
10/21 GLOBAL BLOOD TESTING MARKET 2016 : Abbott Laboratories, Ortho Clinical Diagnosti..
10/21 DGAP-NEWS : Abbott Laboratories: Statement re Delisting From Exchange
10/20 ABBOTT LABORATORIES : An Application for the Trademark "SIMILAC NEWBORN" Has Bee..
10/20 ABBOTT LABORATORIES : An Application for the Trademark "TRUSTED BY PLAYERS. PROV..
10/20 ABBOTT LABORATORIES : An Application for the Trademark "HI-TORQUE VERSACORE" Has..
10/20 ABBOTT LABORATORIES : People's Republic of China Clears Abbott Acquisition of Al..
10/20 ABBOTT LABORATORIES : Jones Collombin Investment Counsel Inc Lowers stake in Abb..
10/20 ABBOTT LABORATORIES : Gemmer Asset Management buys $153,941 stake in Abbott Labo..
More news
Sector news : Pharmaceuticals - NEC
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
10/25 ChemChina ready for concessions to clinch delayed Syngenta deal in 2017 - sou..
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines
10/25DJMARKET SNAPSHOT : U.S. Stock Futures Point To Modest Gains, With Apple Set To Ta..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/25 My Dividend Growth Portfolio - Q3 2016 Summary
10/21 60% Return From Reynolds' Smoking Hot Opportunity
10/21 Alere shareholders back Abbott deal
10/20 SetPoint Leads The Crohn's Medtech Race By Being The Only Entrant
10/20 Don't Worry, It's About To Get Worse